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OBJECTIVE: The estimated annual incidence of venous throm-
boembolism (VTE) is 5–12 per 10,000 and ~10% of hospital
deaths are attributable to pulmonary embolism (PE). Despite
prophylaxis, 1–3% of patients undergoing major orthopaedic
surgery (MOS) develop symptomatic deep vein thrombosis
(DVT). The incidence of recurrent VTE (DVT and PE) is ~20%
and 33–50% of patients develop post-thrombotic syndrome
(PTS). Despite the extensive health care burden of VTE, there is
no systematic review of the associated costs. The objective of this
study was to estimate the costs of VTE in the general population,
and in patients undergoing MOS. METHODS: A systematic
literature review was performed, which focused on “all-cause”
VTE and VTE following MOS. Included studies had to identify
and measure, in clinical practice, health care utilization and the
economic consequences of VTE and associated complications,
including recurrent VTE, PTS and bleeding events. RESULTS:
Annual costs per patient for all-cause VTE were $10,804–33,200
in the US and ~€4000 in Europe. Following MOS, annual treat-
ment costs per patient for VTE were €8265 in Europe. In the US,
charges for the surgical admission were $52,037 for patients with
VTE compared to $34,485 for those without. Complications
associated with VTE and its treatment, described above, were
frequent. Following MOS, the 1-year cumulative incidence of
recurrent DVT was ~24%, ~6.5% for PE, with additional annual
treatment costs in the US of up to $6400. European studies
suggest that, despite the low cost of prophylaxis, the overall costs
of VTE are approximately half the costs associated with MOS.
The main cost drivers were inpatient care and hospitalization for
recurrent events. CONCLUSION: VTE occurs frequently and
is a major cost and resource burden for health care systems,
particularly after MOS. Prophylaxis regimens that can reduce the
incidence of VTE might enable signiﬁcant cost savings to be
achieved.
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OBJECTIVE: To evaluate and compare the relative medical costs
associated with up-titration of statin therapy (Rosuvastatin,
Atorvastatin, Simvastatin, Pravastatin) in order to reach Cana-
dian Lipid Goals. METHODS: Efﬁcacy measures and Canadian
LDL-C goal attainment rates on the studied statins were derived
from a head to head RCT (McKenney JM et al. 2003). The need
for up-titration was modeled during 3-month intervals for a
period of one year based on the goal attainment rates for each
statin and dose. The total number of physician visits and
up-titration from the initial start dose to target lipid goals was
captured and associated medical costs were calculated. Medical
costs consisting of the physician visits and lab costs were derived
from the Ontario Health Insurance (OHIP) Schedule of Beneﬁts
and Fees. RESULTS: After initiation on 10 mg for each statin,
out of a cohort of 100 patients for each treatment arm, 15
patients required dose up-titration to target lipid goals with
Rosuvastatin, 32 with Atorvastatin, 34 with Simvastatin, and
56 with Pravastatin. Additional up-titration to higher doses was
further required for 1 patient on Rosuvastatin, 8 on Atorvastatin,
13 on Simvastatin and 20 patients on Pravastatin. Over one year,
16% of patients treated with Rosuvastatin need to be titrated
compared with 40% on Atorvastatin, 47% on Simvastatin and
76% on Pravastatin. Total costs for general physician visits and
up-titration was estimated to be $6516 for Rosuvastatin, $7849
for Atorvastatin, $8244 for Simvastatin, and $9834 for Pravas-
tatin. CONCLUSION: Statins differ in efﬁcacy at getting patients
to target lipid goals. Differences in efﬁcacy can translate for a
need of dose titration, and potential increased costs in direct
medical expense. This analysis shows that Rosuvastatin may
offer increased savings in physician visits and lab costs since
fewer patients need to be up-titrated to meet target lipid goals.
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OBJECTIVE: Cardiovascular endpoint trials are increasingly
being performed in phase IV evaluations of antihypertensive,
cholesterol-lowering, and glucose-lowering medications. To
facilitate the conduct of economic evaluations in such studies, we
developed a ﬂexible tool to permit researchers to assign medical-
care costs to events commonly included in cardiovascular end-
point trials. METHODS: We used econometric techniques to ﬁt
generalized linear models to administrative data (Ingenix) on
longitudinal costs of care for patients experiencing various
cardiovascular events, including myocardial infarction, cardiac
arrest, stroke (hemorrhagic & ischemic), transient ischemic event
(TIA), revascularization procedures (CABG, PTCA, stenting),
and various cardiovascular-related hospitalizations. Separate
regression equations were estimated for patients who had these
events as well as for their propensity-score matched controls.
Costs of care (net of controls) were estimated on a monthly basis
for the ﬁrst 36 months following each event and then annually
thereafter, with differences in survival between cases and controls
factored into the longitudinal cost calculations. The regression
models included covariates for age, sex, cardiovascular disease
history, and comorbidity proﬁle to permit differential estimation
of event costs for patients of varying characteristics, as would be
observed in cardiovascular endpoint trials. RESULTS: Mean
costs of care (2006 US$) for fatal events were $18,970 for MI,
$12,630 for cardiac arrest, $19,830 for hemorrhagic stroke, and
$11,930 for ischemic stroke. Mean costs over 36 months for
nonfatal events were $36,370 for MI, $36,020 for resuscitated
cardiac arrest, $59,270 for hemorrhagic stroke, $30,150 for
ischemic stroke, $8190 for TIA, $30,650 for CABG, and
$27,780 for PTCA with stenting. Results differ by age, sex, and
patient characteristics. CONCLUSION: The costing tool permits
rapid assignment of medical-care costs to events occurring in
cardiovascular endpoint trials. Widespread use of this tool will
permit standardization of event costing in piggyback economic
evaluations in endpoint trials as well as in cardiovascular
modeling studies.
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